Herriot Tabuteau
Founder, Chairman, CEO & PresidentDr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Financial Officer at Axsome Therapeutics, Inc. since May 9, 2018 until May 16, 2018. Dr. Tabuteau is also the Founder and Managing Member at Antecip Capital LLC (formerly Versant Capital Management, LLC). Dr. Tabuteau is also the managing member of Antecip Bioventures II Limited Liability Company. Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. He was an Analyst-Medical Products at Montgomery Securities. He began his professional career as an investment banking analyst at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School Medical and his B.A. in molecular biology and biochemistry from Wesleyan University.
Positions
- Company NameAxsome Therapeutics, Inc.Stock CodeAXSMPositionFounder, Chairman, CEO & PresidentColleagues
- NPNick PizzieChief Financial Officer
- MLMark L. JacobsonChief Operating Officer
- HMHunter MurdockGeneral Counsel & Secretary
- AMAri MaizelChief Commercial Officer
- RARoger A. JeffsIndependent Director
- MEMark E. SaadIndependent Director
- MCMark ColemanIndependent Lead Director
- SMSusan M. MahonyIndependent Director
